Some ideas in wound healing deserve a second look precisely because they are so simple. Sugar is one of them.
Back in 2010, Biswas, Bharara, Hurst, Gruessner, Horacio Rilo and I reviewed the use of sugar in healing diabetic ulcers. The question remains worth asking: could an inexpensive, widely available material earn a carefully defined place in wound care?
Too dilute is not enough
The central concept is water activity: how much water is available for microorganisms to use. Concentrated sucrose ties up water and creates osmotic stress that can inhibit bacterial growth. Laboratory work by Chirife and colleagues provides a microbiological basis for this effect.
A dilute sugar solution cannot be assumed to reproduce the antibacterial effect of concentrated sugar. A 2020 laboratory study of food-associated pathogens likewise found that high sugar concentrations inhibited growth while very low concentrations could support it; this was not a clinical wound trial. Wound fluid changes the concentration over time. That makes formulation, exudate, wound size and the duration of effective exposure central research questions, rather than minor practical details.
The image of a sugar packet is a useful reminder that this concept concerns a substantial local concentration, not a trace of sweetness. But a packet is not a validated dose, a sterile wound product or an instruction to treat a wound at home. The clinically relevant question is what concentration is maintained at the wound interface, and whether it is effective and safe there. Nor is topical sucrose a reason to relax systemic glucose management.
What else might sugar do?
Our earlier review discussed potential effects on edema, wound cleansing, odor and the local inflammatory environment. Fluid movement could help explain some of these observations. Reduced microbial activity could also reduce odor-producing metabolites. A 2009 uncontrolled audit of 71 patients reported reduced odor and discomfort over ten days. That supports a clinical observation, not proof of a specific mechanism or faster complete healing.
There are intriguing cell-level data, but they need careful separation. A 2006 laboratory study examined sugar and a sugar–povidone-iodine preparation, reporting changes in fibroblast and keratinocyte functions, including collagen synthesis. A 2007 mouse study of a sugar–povidone-iodine mixture found improved epithelial repair and reduced MRSA burden. Results from an iodine-containing mixture cannot establish the clinical effects of plain sucrose.
The story is not uniformly “more sugar, more repair.” Another cell-culture study found that high sucrose concentrations reduced collagen expression and synthesis in granulation-tissue fibroblasts. Concentration, formulation and experimental model matter. Claims that ordinary sugar reliably stimulates collagen, recruits beneficial immune cells or creates new blood vessels in human wounds would get ahead of the evidence.
What has changed since 2010?
There is a small human signal for wound-bed preparation. In Moses Murandu’s 2015 doctoral research, an under-recruited randomized trial analyzed 22 patients assigned to sugar and 19 to usual care. Debridement at four weeks occurred in 19 versus six patients. That is encouraging, but debridement is not complete healing, and this small mixed-wound study does not establish routine use for diabetic foot ulcers.
Some of the strongest newer “sugar” findings concern different molecules. In the EXPLORER randomized trial, a sucrose octasulfate dressing achieved closure at 20 weeks in 48% of patients versus 30% with the control dressing. The population had noninfected neuroischemic diabetic foot ulcers. Sucrose octasulfate is chemically modified; those results do not validate table sugar.
At the experimental end, a 2026 study of 2-deoxy-D-ribose and zinc oxide in dissolving microneedle patches reported improved repair and blood-vessel formation in a rat wound model. This is an interesting delivery-system study involving a different sugar, other active components and a preclinical model. It is not evidence that granulated sucrose produces the same response in patients.
Low cost deserves serious science
There is a broader global-access question here, much as there is with properly formulated Dakin’s solution: can we make effective wound care more accessible without sacrificing safety or evidence? Dakin’s solution acts through reactive chlorine chemistry, not sucrose’s water-activity mechanism. Experimental work on Dakin’s solution also shows why concentration, exposure and tissue compatibility matter. Inexpensive does not mean interchangeable, harmless or ready for universal adoption.
A useful next step would be pragmatic trials of standardized, quality-controlled sucrose formulations alongside good wound care, measuring complete healing, infection, pain, adverse effects, dressing workload and total cost. Those trials should explicitly track dilution by exudate. Global access should be designed into the research from the start.
An oldie but a goodie? Perhaps. Certainly an old idea deserving a modern test. The goal is affordable healing supported by evidence, while keeping perfusion, pressure relief, appropriate debridement and infection management at the center of care.
This discussion is for education and research, not a recipe for self-treatment. A diabetic foot wound needs prompt professional assessment.
Leave a Reply